MOTS-c vs SS-31
Both MOTS-c and SS-31 are used for longevity. Here's how their evidence, dosing, and regulatory status actually compare.
MOTS-c
Evidence BMitochondrial-derived peptide MOTS-c
A 16-amino-acid mitochondrial-derived peptide that improves insulin sensitivity and exercise capacity in animal models. Among the most promising 'mitokines' for metabolic aging.
View full MOTS-c profile →SS-31
Evidence B+Elamipretide (SS-31)
A cell-permeable tetrapeptide that targets cardiolipin in the inner mitochondrial membrane. Investigated for primary mitochondrial myopathy, heart failure, and dry age-related macular degeneration.
View full SS-31 profile →Side-by-Side
| Attribute | MOTS-c | SS-31 |
|---|---|---|
| Evidence Grade | B | B+ |
| FDA Status | Not FDA-approved — research peptide; multiple early-phase clinical trials | Not FDA-approved — Phase 3 trials for primary mitochondrial myopathy |
| Typical Dose | 5–10 mg, 2–3 times weekly (subcutaneous) | Trial range: 40 mg subcutaneous daily |
| Clinics Indexed | 22 | 29 |
| Categories | metabolic, longevity | mitochondrial, longevity |
Key reported benefits — MOTS-c
- ✓Insulin sensitivity
- ✓Exercise capacity
- ✓Metabolic flexibility
Key reported benefits — SS-31
- ✓Mitochondrial cardiolipin support
- ✓ATP production
- ✓Reduced oxidative damage
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.